News

Future trends in Bladder Cancer treatment

BCa19, held in Turin on 17-18 May, is set to bring together a lot of opinion leaders in bladder cancer who will be giving very practical talks and case-based discussions that will cover many aspects of BCa treatment relevant...

BCa18: Benefits of ERAS following radical cystectomy

Radical cystectomy is the standard for muscle-invasive bladder cancer and with mostly elderly men as patients, doctors are seeking ways to improved recovery regimes following radical surgeries. “64% of patients have one or more complications, 13% have a major...

BCa18: Gains and prospects in BCa classification and treatment

There are increment developments in genomics research on bladder cancer (BCa) molecular classification, but drug development and their prospective benefits still remain unclear due to the complex types of aggressive disease and the lack of sufficient patient numbers in...

Identifying potential road maps in personalising BCa treatment

Bladder cancer, one of the most aggressive recurrent onco-urological malignancies, poses a special challenge to cancer experts due to the lack of response from many patients particularly  those who are diagnosed at a late stage. The EAU Update on...

Advances in classifying BCa variants to boost therapeutic options

Recent gains in precisely identifying bladder cancer variants and their respective classification can go a long way in enabling physicians to determine the proper treatment, which leads to better or timely therapies for many bladder cancer patients. Bladder cancer...

Identifying high-risk patients: Key for optimal BCa management

For many physicians bladder cancer management is replete with challenges and pitfalls, and with the recent developments in drug development and molecular classifications, specialists encounter dilemmas that prompt a critical look at both current practices and novel treatment options....